|Dr. Weidong Yin||Chairman, Pres, CEO & Sec.||N/A||N/A||1965|
|Ms. Nan Wang||CFO & VP of Bus. Devel.||N/A||N/A||1966|
|Mr. Ming Xia||VP of Sales & Marketing||N/A||N/A||1974|
Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B, enterovirus 71 (EV71), seasonal influenza, H5N1 and H1N1 pandemic influenza, and mumps, as well as hand, foot, and mouth diseases. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also completed phase III clinical trials for varicella and pneumococcal polysaccharide vaccines. In addition, it has completed Phase III clinical trials for Sabin inactivated polio; and focuses on commencing clinical trials for pneumococcal conjugate vaccine, rubella vaccine, and quadrivalent influenza vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; and Tianjin CanSino Biotechnology Inc. to develop a pneumococcal conjugate vaccine. Sinovac Biotech Ltd. was founded in 1999 and is based in Beijing, the People's Republic of China.
Sinovac Biotech Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.